Boston Scientific (BSX) shares fell Wednesday when the medical equipment manufacturer's third-quarter profit fell and its GAAP earnings per share (EPS) came in short of its guidance.
Boston Scientific registers year-over-year improvement in sales, indicating solid market share gains in legacy businesses despite macroeconomic odds.
Boston Scientific Corporation (NYSE:BSX ) Q3 2024 Earnings Conference Call October 23, 2024 8:00 AM ET Company Participants Jonathan Monson - Senior Vice President, Investor Relations Michael Mahoney - Chairman and Chief Executive Officer Daniel Brennan - Executive Vice President and Chief Financial Officer Kenneth Stein - Senior Vice President, Global Chief Medical Officer Conference Call Participants Robert Marcus - JPMorgan Joanne Wuensch - Citigroup Inc. Lawrence Biegelsen - Wells Fargo Securities Frederick Wise - Stifel, Nicolaus & Company David Roman - Goldman Sachs Patrick Wood - Morgan Stanley Travis Steed - Barclays Bank Danielle Antalffy - UBS Anthony Petrone - Mizuho Group Vijay Kumar - Evercore ISI Matt Miksic - Barclays Joshua Jennings - TD Cowen Matthew O'Brien - Piper Sandler Operator Good morning and welcome to the Boston Scientific Third Quarter 2024 Earnings Call. All participants will be in listen-only mode.
The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Boston Scientific (BSX) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.50 per share a year ago.
Medical-products company Boston Scientific reported third-quarter results before market open.
Boston Scientific raised its annual profit forecast and exceeded Wall Street's estimates for third-quarter profit on Wednesday, driven by robust demand for its heart devices, sending its shares higher 1.1% to $88.94 in premarket trading.
Boston Scientific earnings and sales beat Q3 views early Wednesday. The medtech giant's shares, right at record highs, rose before the open,
Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.
Get a deeper insight into the potential performance of Boston Scientific (BSX) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Boston Scientific (BSX) concluded the recent trading session at $87, signifying a +0.27% move from its prior day's close.